Question · asked by 1 review
CLOZAPINE + RISPERIDONE vs CLOZAPINE + ZIPRASIDONE (Kuwilsky 2010): Clinical response: mean score/change in global state: mean CGI‐II Global improvement score (high = poor) Short term (6 weeks)
- Population
- people with treatment‐resistant schizophrenia
- Intervention
- CLOZAPINE + RISPERIDONE
- Comparison
- CLOZAPINE + ZIPRASIDONE (Kuwilsky 2010)
- Outcome
- Clinical response: mean score/change in global state: mean CGI‐II Global improvement score (high = poor) Short term (6 weeks)
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
CLOZAPINE + RISPERIDONE vs CLOZAPINE + ZIPRASIDONE (Kuwilsky 2010) Clinical response: mean score/change in global state: mean CGI‐II Global improvement score (high = poor) Short term (6 weeks) · people with treatment‐resistant schizophrenia Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia (2017) · Cochrane Headline outcomes only | no estimate extracted | 1 study · 22 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia 2017 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.